PAVmed (PAVM) AI Stock Analysis

• Market Cap: $11.04M
• Dividend Yield: N/A
• Average Volume (3M): 195.66K
• Price to Earnings (P/E): 0.9
• Beta (1Y): 1.75
• Revenue Growth: -33.92%
• EPS Growth: N/A
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): 0.34
• Shares Outstanding: 17,294,619
• 10 Day Avg. Volume: 167,322
• 30 Day Avg. Volume: 195,664
• PEG Ratio: >-0.01
• Price to Book (P/B): -4.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.59
• Enterprise Value/Market Cap: 3.46
• Enterprise Value/Revenue: 1.83
• Enterprise Value/Gross Profit: -1.29
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $11.50
• Price Target Upside: 1696.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 53 Neutral
• Price Target: $0.50 ▼(-21.88%Downside)

PAVmed's overall stock score reflects a combination of financial challenges and strategic positives. While the company is on a path of strategic expansion and has shown some financial improvements, significant operational and cash flow issues remain. The technical indicators suggest bearish momentum, and while the valuation appears favorable, the lack of dividends and high leverage are concerns. The earnings call highlighted strategic initiatives that slightly outweigh the risks, contributing positively to the score.

Positive Factors

Commercialization efforts

Veris Health completed a pilot program with a major cancer center and is finalizing a commercial contract, indicating progress in its commercialization efforts.

Medicare coverage

Lucid Diagnostics reported strong EsoGuard testing results and is expected to receive Medicare coverage, which could drive further growth.

Negative Factors

Revenue projections

Revenue estimates for 2025 and 2026 have been lowered due to a slower expected ramp in patients.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

How the Company Makes Money

PAVmed generates revenue primarily through the commercialization and sale of its medical devices and technologies. The company earns income from product sales, licensing agreements, and potential partnerships with healthcare providers and distributors. PAVmed's business model focuses on advancing its pipeline of medical technologies to commercialization, thereby increasing its market presence and revenue streams. The company's earnings are influenced by factors such as product adoption rates, pricing strategies, regulatory approvals, and the expansion of its distribution networks. Strategic partnerships and collaborations in the healthcare industry also play a significant role in enhancing PAVmed's market reach and financial performance.

PAVmed Financial Statement Overview

Summary

PAVmed's financial performance shows substantial challenges despite some improvements. Revenue growth is notable, but persistent operational losses and negative cash flows are concerning. The balance sheet indicates high leverage, posing risks to financial stability.

Income Statement

PAVmed's income statement reveals substantial challenges. The TTM (Trailing-Twelve-Months) data shows a negative gross profit margin and EBIT margin, indicating significant operational losses. Despite a remarkable increase in total revenue, net income remains highly volatile, underscored by a net profit margin that is skewed due to a large net income figure possibly influenced by extraordinary items. The revenue growth rate is impressive but is overshadowed by persistent negative profitability margins.

Balance Sheet

The balance sheet presents a mixed picture. While total assets have grown significantly, the debt-to-equity ratio is concerning, with substantial negative equity in previous years turning positive this year. The equity ratio has improved, suggesting better asset management, but the high total liabilities relative to equity indicate potential risks. Overall, financial stability appears fragile despite recent improvements.

Cash Flow

Cash flow analysis indicates that PAVmed struggles with cash generation. Operating cash flow is negative in the TTM period, reflecting operational inefficiencies. The free cash flow remains negative, highlighting issues in converting revenue into cash. Although there are significant financing inflows, reliance on external financing remains high. The operating cash flow to net income ratio is unfavorable, suggesting a disconnect between accounting profits and cash flows.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.98M	3.00M	2.45M	377.00K	500.00K	0.00
	Gross Profit
-29.48M	-1.84B	-3.97M	-3.24M	-85.00K	-23.00K
	EBIT
-5.48B	-44.49B	-68.80M	-90.93M	-54.39M	-23.35M
	EBITDA
-5.40B	-44.49B	-75.74M	-99.41M	-55.90M	-35.81M
	Net Income Common Stockholders
17.75B	39.79M	-64.17M	-101.29M	-50.35M	-34.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.70B	1.19B	19.64M	39.74M	77.26M	17.26M
	Total Assets
52.82B	30.66M	33.12M	53.98M	86.98M	19.78M
	Total Debt
9.24B	31.86M	48.73M	36.64M	0.00	14.96M
	Net Debt
6.54B	30.68M	29.09M	-3.11M	-77.26M	-2.30M
	Total Liabilities
11.89B	37.69M	57.14M	43.05M	7.56M	20.25M
	Stockholders Equity
44.99B	-2.50B	-53.83M	-9.68M	61.67M	1.90M
Cash Flow		Free Cash Flow
-1.60B	-33.61M	-52.28M	-72.53M	-42.06M	-21.97M
	Operating Cash Flow
-1.60B	-33.55M	-52.04M	-70.98M	-40.59M	-21.91M
	Investing Cash Flow
-22.14M	-16.18M	758.00K	-4.74M	-3.72M	-55.00K
	Financing Cash Flow
3.11B	31.28M	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.68, and below the 200-day MA of 0.86, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.58 is Neutral, neither overbought nor oversold. The STOCH value of 82.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
PAVM	53 Neutral	$11.04M	0.90	-499.57%	―	-33.92%	―
BRTX	48 Neutral	$12.61M	―	-117.16%	―	175.03%	55.34%
SNSE	40 Underperform	$7.56M	―	-64.18%	―	―	1.00%
SPRB	35 Underperform	$3.15M	―	-135.33%	―	-51.32%	-1.76%
TRAW	28 Underperform	$9.40M	―	-576.08%	―	―	-404.67%
MGRX		$20.07M	―	-115.87%	―	―	―

PAVmed Corporate Events

PAVmed Reports Q1 2025 Financial Results and Updates

On May 15, 2025, PAVmed Inc. provided a business update and reported its first-quarter financial results for 2025. Lucid Diagnostics secured capital to extend its runway beyond key reimbursement milestones and reported $0.8 million in revenue from its EsoGuard Esophageal DNA Test. Veris Health resumed development of its implantable physiological monitor and is set to launch a commercial partnership with a major cancer center. PAVmed is actively seeking to expand into the biopharma sector, evaluating clinical and late preclinical-stage assets. Financially, PAVmed ended the first quarter with over $40 million in pro forma cash, and its operating expenses were approximately $5.5 million, resulting in a GAAP net income of $17.7 million.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.